Indaptus Therapeutics, Inc. (INDP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Indaptus Therapeutics, Inc. (INDP) closed at USD 2.21 on 2026-10-14, a change of -35.9 % over the past year, with a market capitalization of USD 379.74M.

Indaptus Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Indaptus Therapeutics, Inc. key figures

Previous close

USD 2.21 (2026-10-14)

1-year change

-35.9 %

Market cap

USD 379.74M

Enterprise value

USD 368.19M

P/E ratio (trailing)

-0.39

P/E ratio (forward)

-2.05

EPS (trailing)

-7.28

EPS (forward)

-1.39

PEG ratio

n/a

Price to book

33.53

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.56

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Indaptus Therapeutics, Inc. and compare it with other stocks.